v3.26.1
Segment information (Tables)
6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Financial Data for the Company's Reportable Segment

The following table presents certain financial data for the Company’s reportable segment, including significant segment expenses regularly provided to the chief operating decision maker to assess performance of the Company.

 

 

 

Three Months Ended
June 30,

 

 

Six Months Ended
June 30,

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

 

($'000)

 

 

($'000)

 

 

($'000)

 

 

($'000)

 

Revenue

 

$

 

 

$

500

 

 

$

 

 

$

500

 

Cost of revenue

 

 

 

 

 

(132

)

 

 

 

 

 

(132

)

Research and development expenses

 

 

 

 

 

 

 

 

 

 

 

 

Setrusumab (BPS-804/UX143)

 

 

(1,112

)

 

 

(3,687

)

 

 

(5,164

)

 

 

(5,930

)

Alvelestat (MPH-966)

 

 

(426

)

 

 

(1,396

)

 

 

(869

)

 

 

(2,761

)

Etigilimab (MPH-313)

 

 

(220

)

 

 

(224

)

 

 

(414

)

 

 

(431

)

Other

 

 

(50

)

 

 

(66

)

 

 

(108

)

 

 

(181

)

General and administrative expenses

 

 

(5,222

)

 

 

(5,494

)

 

 

(9,241

)

 

 

(12,766

)

Other segment items

 

 

25

 

 

 

(4,117

)

 

 

2,072

 

 

 

(5,802

)

Net loss before income tax

 

$

(7,005

)

 

$

(14,616

)

 

$

(13,724

)

 

$

(27,503

)